A 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Lumateperone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- 15 Sep 2017 New trial record
- 07 Sep 2017 According to an Intra-Cellular Therapies media release, further data from this study will be presented at upcoming medical conferences.
- 07 Sep 2017 Topline results from the open label part of the study (n=302), published in an Intra-Cellular Therapies media release.